Af­ter ramp­ing up its vac­cine pro­duc­tion in South Africa, As­pen yet to re­ceive a sin­gle or­der

When As­pen Phar­ma­care made an agree­ment with J&J to make and sell its own gener­ic Covid-19 vac­cine much of the world re­joiced. As­pen CEO Stephen Saad said that it would help catch Africa up to speed with the rest of the world, and Pres­i­dent Joe Biden’s ad­min­is­tra­tion agreed and pledged $200 mil­lion to the plant in Gqe­ber­ha to ex­pand pro­duc­tion.

But now, de­spite be­ing the first fac­to­ry in Africa to make vac­cines for the con­ti­nent, the phar­ma has not re­ceived a sin­gle or­der, which could lead to the shut­ter­ing of the site, ac­cord­ing to a re­cent re­port from The New York Times.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.